COMP <GO>
RGEN vs KRYS // OPERATING MARGIN
Repligen Corporation (NASDAQ) VS. Krystal Biotech Inc. (NASDAQ) • 15-METRIC TALLY: RGEN 2
— KRYS 8
▲ OPERATING MARGIN LEADER: KRYS
LAST: $172.95 (-2.25%) • MKT CAP: $10.03B
operating-margins
1.80%
LAST: $295.90 (-10.95%) • MKT CAP: $9.84B
operating-margins
41.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RGEN VS. KRYS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RGEN | KRYS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.20% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 2.30% | 16.50% | -14.20 | KRYS | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | 53.4x | +41.60 | KRYS | /valuation <GO> |
| Free Cash Flow Yield | 0.88% | 1.97% | -1.09 | KRYS | /fcf-yield <GO> |
| Operating Margin ACTIVE | 1.80% | 41.50% | -39.70 | KRYS | /operating-margins <GO> |
| Net Profit Margin | 1.60% | 52.60% | -51.00 | KRYS | /net-margins <GO> |
| Revenue Growth (YoY) | -3.30% | 33.90% | -37.20 | KRYS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.31 | 26.00 | -16.69 | KRYS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.0 | 53.8 | -5.80 | KRYS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.04 | 0.91 | +0.13 | RGEN | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 39.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.03B | $9.84B | $195.8M | RGEN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RGEN REV | KRYS REV | RGEN GROSS % | KRYS GROSS % | RGEN FCF | KRYS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $154.5M | $389.1M | — | — | $93.9M | $188.9M |
| FY 2024 | $98.3M | $290.5M | — | — | $149.7M | $119.2M |
| FY 2023 | $133.6M | $50.7M | — | — | $113.9M | -$91.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RGEN // BETA 1.04
KRYS // BETA 0.91